Progress of diagnosis and treatment of cytokine release syndrome after CD19 chimeric antigen receptor T cells therapy / 白血病·淋巴瘤

ABSTRACT

CD19 chimeric antigen receptor T cells (CAR-T) therapy is a new immunotherapy for B-cell hematological tumors, and has good efficacy. With the increase of its use, the incidence of immune effector cell-associated cytokine release syndrome is increasing, and further clinical research on its precise mechanism and treatment is urgently needed. This review summarizes the mechanisms, clinical manifestations, grading systems, treatments and management strategies of cytokine release syndrome.